Literature DB >> 24962974

Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment.

Johanna Benhamou1, Deborah Gensburger2, Roland Chapurlat2.   

Abstract

Entities:  

Keywords:  Bisphosphonate; Denosumab; Fibrous dysplasia of bone; RANKL

Mesh：

Substances：

Year:  2014        PMID： 24962974     DOI： 10.1016/j.jbspin.2014.04.013

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  11 in total

Review 1.  Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives.

Authors:  Cemre Robinson; Michael T Collins; Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 2.  Fibrous dysplasia of bone: craniofacial and dental implications.

Authors:  A B Burke; M T Collins; A M Boyce
Journal:  Oral Dis       Date:  2016-09-01       Impact factor: 3.511

Review 3.  Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review.

Authors:  Iris Hartley; Maria Zhadina; Micheal T Collins; Alison M Boyce
Journal:  Calcif Tissue Int       Date:  2019-04-29       Impact factor: 4.333

4.  Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia.

Authors:  Cristina Eller-Vainicher; Diego Sergio Rossi; Giuseppe Guglielmi; Giada Anna Beltramini; Elisa Cairoli; Antonio Russillo; Giovanna Mantovani; Anna Spada; Iacopo Chiodini
Journal:  Clin Cases Miner Bone Metab       Date:  2017-02-10

Review 5.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

Review 6.  Understanding osteoporotic pain and its pharmacological treatment.

Authors:  R Vellucci; R Terenzi; J A Kanis; H G Kress; R D Mediati; J-Y Reginster; R Rizzoli; M L Brandi
Journal:  Osteoporos Int       Date:  2018-04-04       Impact factor: 4.507

7.  RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease.

Authors:  Biagio Palmisano; Emanuela Spica; Cristina Remoli; Rossella Labella; Annamaria Di Filippo; Samantha Donsante; Fabiano Bini; Domenico Raimondo; Franco Marinozzi; Alan Boyde; Pamela Robey; Alessandro Corsi; Mara Riminucci
Journal:  J Bone Miner Res       Date:  2019-08-21       Impact factor: 6.390

Review 8.  Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.

Authors:  Marlous Rotman; Neveen Agnes Therese Hamdy; Natasha M Appelman-Dijkstra
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

Review 9.  Advances in Models of Fibrous Dysplasia/McCune-Albright Syndrome.

Authors:  Hsuan Lung; Edward C Hsiao; Kelly L Wentworth
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-24       Impact factor: 5.555

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.